Copyright
©The Author(s) 2018.
World J Clin Oncol. Dec 20, 2018; 9(8): 188-199
Published online Dec 20, 2018. doi: 10.5306/wjco.v9.i8.188
Published online Dec 20, 2018. doi: 10.5306/wjco.v9.i8.188
Figure 2 Interferon-gamma levels measured in mice immunized with 20 µg Survivin (+ Mycobacterium indicus pranii) and 50 µg Survivin (+ Mycobacterium indicus pranii) in comparison to phosphate buffer saline administered control mice and Mycobacterium indicus pranii administered mice.
Interferon-gamma is expressed as fold change relative to the levels obtained in phosphate buffer saline administered mice before the tumor challenge. MIP: Mycobacterium indicus pranii.
- Citation: Garg H, Hada RS, Gupta JC, Talwar GP, Dubey S. Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model. World J Clin Oncol 2018; 9(8): 188-199
- URL: https://www.wjgnet.com/2218-4333/full/v9/i8/188.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i8.188